scholarly journals The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

2021 ◽  
Vol 10 (3) ◽  
Author(s):  
Meng‐Jia Song ◽  
Qiu‐Zhong Pan ◽  
Ya Ding ◽  
Jianxiong Zeng ◽  
Pei Dong ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Cell Immunotherapy ◽  
Phase 2 Study ◽  
Cik Cell

scholarly journals Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

2007 ◽  
Vol 13 (22) ◽  
pp. 6689-6695 ◽  
Author(s):  
Scot Ebbinghaus ◽  
Maha Hussain ◽  
Nizar Tannir ◽  
Michael Gordon ◽  
Apurva A. Desai ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Study

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

2016 ◽  
Vol 69 (5) ◽  
pp. 767-770 ◽  
Author(s):  
Constantijn H.J. Muselaers ◽  
Marye J. Boers-Sonderen ◽  
Tim J. van Oostenbrugge ◽  
Otto C. Boerman ◽  
Ingrid M.E. Desar ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Monoclonal Antibody ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carbonic Anhydrase Ix ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document